The Evolutionary Landscape of Treatment for <i>BRAF<sup>V600E</sup></i> Mutant Metastatic Colorectal Cancer
The <i>BRAF<sup>V600E</sup></i>mutation is found in 8–10% of metastatic colorectal cancer (mCRC) patients and it is recognized as a poor prognostic factor with a median overall survival inferior to 20 months. At present, besides immune checkpoint inhibitors (CPIs) for those t...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/1/137 |